UK Confirms Indefinite CE Mark Recognition For Medical Devices 2026: EU MDR, IVDR And Great Britain Compliance Guide

What the UK Government’s New Decision Means for Medical Device Manufacturers, IVD Companies, Importers, Distributors and Regulatory Affairs Professionals

The United Kingdom is taking an important step towards strengthening medical device market access by confirming the indefinite recognition of CE-marked medical devices and in vitro diagnostic medical devices (IVDs) in Great Britain.

On 21 October 2026, the UK Government confirmed its decision to continue recognizing CE-marked medical devices certified under the EU Medical Device Regulation (EU MDR 2017/745) and the EU In Vitro Diagnostic Medical Device Regulation (EU IVDR 2017/746) on an indefinite basis.

The decision provides greater regulatory certainty for manufacturers supplying medical devices to England, Scotland and Wales. It is also expected to reduce duplicative conformity assessment requirements, support continuity of supply and maintain patient access to essential medical technologies.

However, legislative implementation is still required and remains subject to parliamentary approval. The MHRA intends to implement the changes before 30 June 2028.

Importantly, the decision does not eliminate all UK medical device regulatory obligations. MHRA registration, UK Responsible Person requirements, applicable post-market surveillance (PMS) obligations and other Great Britain-specific requirements will continue to apply.

For medical device manufacturers, IVD developers, importers and distributors, this announcement represents an important development in long-term UK regulatory planning.

Why Indefinite CE Recognition Matters for the Medical Device Industry

Following Brexit, Great Britain established a separate regulatory framework under the UK Medical Devices Regulations 2002. CE marking continued to be recognized through transitional arrangements, with acceptance periods depending on the applicable European legislation and device category.

The Government's October 2026 decision provides a longer-term solution for devices certified under EU MDR and EU IVDR.

The announcement is particularly significant because more than 90% of medical devices registered for use in Great Britain currently carry CE marking, according to the MHRA.

The decision is expected to benefit the medical technology sector through:

• Reduced regulatory duplication: Manufacturers can avoid an additional UKCA conformity assessment solely to maintain GB market access for eligible CE-marked devices.
• Improved market access: Continued recognition supports manufacturers already operating under EU MDR and EU IVDR.
• Patient access: Healthcare providers can benefit from greater continuity in the availability of medical technologies.
• Supply-chain resilience: Reduced regulatory complexity can support product availability and distribution.
• Investment certainly: Manufacturers can plan regulatory strategies, product launches and market expansion with greater predictability.
• International regulatory alignment: Continued recognition supports cooperation with established international regulatory frameworks.

For international medical technology companies, the decision also makes Great Britain a more predictable market for products already certified under the applicable EU regulations.

What Has the UK Government Confirmed?

The Government intends to introduce legislative changes to indefinitely recognize CE-marked medical devices certified under EU MDR and IVDs certified under EU IVDR.

The policy also addresses legacy devices certified under earlier European directives, although these devices will remain subject to separate transitional arrangements.

Key Regulatory Developments

The announcement represents a policy decision rather than an immediate replacement of the existing legislation. Manufacturers should continue following the regulatory requirements currently in force until the relevant amendments take effect.

Important Dates and Implementation Timeline

The announcement follows a targeted consultation conducted by the MHRA between February and April 2026.

Important: Until the legislative changes enter into force, existing Great Britain transitional arrangements continue to apply. Companies should not treat the announcement itself as an immediate extension of every CE-marked device's current eligibility period.

Which Medical Devices and IVDs Are Covered?

The Government's decision specifically concerns medical devices certified under EU MDR and IVDs certified under EU IVDR.

The distinction between newer European regulations and legacy directives is important for manufacturers managing multiple product portfolios.

Legacy devices should not automatically be considered covered by indefinite recognition. Their eligibility remains dependent on the applicable transitional provisions and relevant EU regulatory timelines.

UKCA Marking: Does It Still Matter?

Yes. The UKCA marking route remains available as the domestic conformity assessment pathway for medical devices placed on the Great Britain market.

The Government's decision to continue recognizing eligible CE-marked products does not abolish UKCA requirements or remove the option for manufacturers to pursue UKCA conformity assessment.

Manufacturers should evaluate both routes based on their product portfolios, target markets, certification arrangements and long-term regulatory strategies.

Businesses supplying both Great Britain and the European Union should also consider the different market requirements.

Continuing MHRA Compliance Requirements

Indefinite CE recognition does not mean exemption from Great Britain-specific regulatory obligations.

Manufacturers and other responsible economic operators must continue meeting applicable requirements under the UK Medical Devices Regulations 2002.

Key compliance areas include:

1. MHRA registration: Applicable medical devices and IVDs must be registered with the MHRA before being placed on the Great Britain market.
2. UK Responsible Person: Manufacturers established outside the UK must appoint a UK Responsible Person where required.
3. Post-market surveillance: Manufacturers must comply with applicable Great Britain PMS requirements and maintain appropriate safety monitoring procedures.
4. Vigilance and incident reporting: Relevant safety incidents and field safety corrective actions must be reported in accordance with applicable requirements.
5. Technical documentation: Product conformity evidence, technical documentation and supporting records must remain available.
6. Regulatory monitoring: Manufacturers must monitor legislative amendments and MHRA guidance affecting their products.

These continuing requirements are particularly important for manufacturers relying on CE recognition as their primary route to the GB market.

Who Should Pay Attention?

The Government's decision has implications for businesses across the medical technology supply chain.

2026–2028 Great Britain Medical Device Compliance Readiness Checklist

Manufacturers should use the implementation period to review their regulatory position and prepare for the forthcoming legislative changes.

Impact on Medical Device Manufacturers and Importers

The indefinite recognition decision may influence regulatory investment, certification planning and market-entry strategies.

Manufacturers may benefit from reduced duplication when supplying products already certified under EU MDR and EU IVDR. However, they should not overlook the importance of maintaining EU certification and meeting applicable GB-specific obligations.

Importers and distributors should continue verifying product conformity, registration status and the responsibilities of relevant suppliers.

Companies with legacy MDD, AIMDD or IVDD products should separately evaluate transitional eligibility rather than if the new indefinite recognition policy applies to all CE-marked devices.

For businesses managing products across multiple jurisdictions, regulatory alignment, documentation management and lifecycle compliance will remain important priorities.

Frequently Asked Questions

1. What did the UK Government announce on 21 October 2026?

The Government confirmed its intention to recognize CE-marked medical devices under EU MDR and IVDs under EU IVDR indefinitely in Great Britain.

2. Does indefinite CE recognition mean UKCA marking is no longer required?

No. UKCA remains an available domestic conformity assessment route. Eligible CE-marked devices will be able to access Great Britain without an additional UKCA assessment solely for that purpose once the legislative changes take effect.

3. Does the decision cover EU MDR and EU IVDR devices?

Yes. Both regulatory frameworks are covered by the Government's intended indefinite recognition policy.

4. Are legacy MDD devices included?

Legacy devices remain subject to separate transitional arrangements. They should not automatically be treated as eligible for indefinite recognition.

5. When will the legislative changes be implemented?

The MHRA intends to implement the changes before 30 June 2028, subject to parliamentary approval.

6. Will MHRA registration still be required?

Yes. Applicable medical devices and IVDs must continue to meet MHRA registration requirements before being placed on the Great Britain market.

7. Do overseas manufacturers still need a UK Responsible Person?

Yes. Manufacturers established outside the UK must appoint a UK Responsible Person where required under the applicable regulations.

8. Will post-market surveillance obligations continue?

Yes. Applicable Great Britain post-market surveillance, vigilance and reporting obligations remain important.

9. Does the decision apply to Northern Ireland?

The announcement concerns Great Britain (England, Scotland and Wales). Northern Ireland operates under a separate applicable regulatory framework.

10. Should manufacturers review their regulatory strategies?

Yes. Companies should review certification, product registration, legacy device eligibility, UK Responsible Person arrangements and PMS procedures.

Conclusion

The UK Government's decision to recognize CE-marked medical devices under EU MDR and IVDs under EU IVDR indefinitely is a significant development for the Great Britain medical technology market.

By reducing duplicative conformity assessment requirements and providing greater regulatory certainty, the decision is expected to support manufacturers, strengthen supply resilience and maintain patient access to essential medical technologies.

However, legislative implementation remains pending and subject to parliamentary approval. MHRA registration, UK Responsible Person requirements and applicable post-market surveillance obligations will continue.

Medical device manufacturers, IVD developers, importers and distributors should use this period to review their certification strategies, assess legacy device portfolios and strengthen their Great Britain regulatory compliance programmers.

How Maven Regulatory Solutions Can Help

Maven Regulatory Solutions supports medical devices and IVD companies with:

• UK medical device regulatory assessments.
• EU MDR and EU IVDR compliance reviews.
• Great Britain market access strategies.
• UKCA and CE mark regulatory assessments.
• MHRA registration support.
• UK Responsible Person regulatory coordination.
• Medical device technical documentation reviews.
• IVD regulatory compliance assessments.
• Post-market surveillance and vigilance support.
• Regulatory gap assessments and compliance audits.
• Product lifecycle management.
• Global medical device regulatory intelligence.

Our approach helps manufacturers, importers and distributors understand evolving regulatory requirements, strengthen compliance processes and develop effective strategies for sustainable access to international medical device markets.